American Oriental Bioengineering, Inc. (AOBI)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2012 | 99.33 Million USD | -2.66% |
| 2011 | 102.04 Million USD | -19.9% |
| 2010 | 127.38 Million USD | 17.93% |
| 2009 | 108.02 Million USD | 11.33% |
| 2008 | 97.02 Million USD | 64.76% |
| 2007 | 58.88 Million USD | 65.95% |
| 2006 | 35.48 Million USD | 111.41% |
| 2005 | 16.78 Million USD | 57.54% |
| 2004 | 10.65 Million USD | 39.85% |
| 2003 | 7.61 Million USD | 92.75% |
| 2002 | 3.95 Million USD | 10585.25% |
| 2001 | 36.99 Thousand USD | -95.63% |
| 2000 | 845.77 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2013 Q1 | 21.15 Million USD | -17.01% |
| 2013 Q3 | 22.08 Million USD | 44.26% |
| 2013 Q2 | 15.3 Million USD | -27.66% |
| 2012 Q1 | 22.77 Million USD | -47.37% |
| 2012 FY | 99.33 Million USD | -2.66% |
| 2012 Q4 | 25.49 Million USD | -0.62% |
| 2012 Q3 | 25.65 Million USD | 0.95% |
| 2012 Q2 | 25.41 Million USD | 11.59% |
| 2011 Q4 | 43.26 Million USD | 119.89% |
| 2011 FY | 102.04 Million USD | -19.9% |
| 2011 Q3 | 19.67 Million USD | 0.56% |
| 2011 Q2 | 19.56 Million USD | 0.18% |
| 2011 Q1 | 19.53 Million USD | -46.42% |
| 2010 Q2 | 30.75 Million USD | 40.64% |
| 2010 Q3 | 38.31 Million USD | 24.57% |
| 2010 Q4 | 36.45 Million USD | -4.84% |
| 2010 Q1 | 21.86 Million USD | -42.01% |
| 2010 FY | 127.38 Million USD | 17.93% |
| 2009 Q2 | 23.34 Million USD | 35.68% |
| 2009 FY | 108.02 Million USD | 11.33% |
| 2009 Q4 | 37.7 Million USD | 29.47% |
| 2009 Q1 | 17.2 Million USD | -52.16% |
| 2009 Q3 | 29.12 Million USD | 24.78% |
| 2008 FY | 97.02 Million USD | 64.76% |
| 2008 Q1 | 14.31 Million USD | -29.28% |
| 2008 Q4 | 35.96 Million USD | 41.9% |
| 2008 Q3 | 25.34 Million USD | 18.41% |
| 2008 Q2 | 21.4 Million USD | 49.53% |
| 2007 Q3 | 16.69 Million USD | 36.9% |
| 2007 Q4 | 20.23 Million USD | 21.2% |
| 2007 Q1 | 9.79 Million USD | -19.79% |
| 2007 FY | 58.88 Million USD | 65.95% |
| 2007 Q2 | 12.19 Million USD | 24.58% |
| 2006 Q4 | 12.2 Million USD | 39.57% |
| 2006 FY | 35.48 Million USD | 111.41% |
| 2006 Q3 | 8.74 Million USD | 8.28% |
| 2006 Q2 | 8.07 Million USD | 30.4% |
| 2006 Q1 | 6.19 Million USD | -7.28% |
| 2005 Q4 | 6.68 Million USD | 73.24% |
| 2005 Q1 | 3 Million USD | -16.34% |
| 2005 Q2 | 3.24 Million USD | 8.23% |
| 2005 Q3 | 3.85 Million USD | 18.75% |
| 2005 FY | 16.78 Million USD | 57.54% |
| 2004 Q3 | 2.27 Million USD | -1.01% |
| 2004 Q2 | 2.29 Million USD | -7.82% |
| 2004 Q1 | 2.49 Million USD | -12.61% |
| 2004 FY | 10.65 Million USD | 39.85% |
| 2004 Q4 | 3.58 Million USD | 57.61% |
| 2003 Q4 | 2.85 Million USD | 52.59% |
| 2003 Q1 | 1.43 Million USD | 58.32% |
| 2003 Q2 | 1.47 Million USD | 2.94% |
| 2003 Q3 | 1.87 Million USD | 26.97% |
| 2003 FY | 7.61 Million USD | 92.75% |
| 2002 Q3 | 1.48 Million USD | 50.23% |
| 2002 Q1 | - USD | 100.0% |
| 2002 FY | 3.95 Million USD | 10585.25% |
| 2002 Q4 | 903.66 Thousand USD | -39.18% |
| 2002 Q2 | 989.07 Thousand USD | 0.0% |
| 2001 Q2 | 35.52 Thousand USD | -49.57% |
| 2001 FY | 36.99 Thousand USD | -95.63% |
| 2001 Q4 | -13.37 Thousand USD | -179.85% |
| 2001 Q3 | 16.75 Thousand USD | -52.85% |
| 2001 Q1 | 70.45 Thousand USD | 29.44% |
| 2000 FY | 845.77 Thousand USD | 0.0% |
| 2000 Q1 | 370.46 Thousand USD | 0.0% |
| 2000 Q2 | 114.7 Thousand USD | -69.04% |
| 2000 Q3 | 306.17 Thousand USD | 166.92% |
| 2000 Q4 | 54.43 Thousand USD | -82.22% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -7338.061% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -1870.038% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -236.109% |
| Nascent Biotech, Inc. | 2.22 Million USD | -4354.509% |
| Rebus Holdings, Inc. | 664 Thousand USD | -14859.363% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -166.618% |
| Qrons Inc. | 643.67 Thousand USD | -15331.679% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -25397.649% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -72.929% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -23807.387% |
| Skye Bioscience, Inc. | 13.54 Million USD | -633.197% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -14.455% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -1919.763% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -37851.969% |
| SQZ Biotechnologies Company | 85.61 Million USD | -16.014% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -3306.11% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -6513.639% |
| Mesoblast Limited | 5.9 Million USD | -1582.992% |
| Marizyme, Inc. | 19.23 Million USD | -416.274% |
| Genus plc | 147.7 Million USD | 32.749% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1031.422% |
| Pharming Group N.V. | 225.49 Million USD | 55.949% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -4748.437% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -7304.162% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1091.152% |
| ContraFect Corporation | 56.88 Million USD | -74.603% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -2153.063% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -6617.162% |
| IMV Inc. | 37.7 Million USD | -163.411% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -3459.766% |
| MultiCell Technologies, Inc. | 567.42 USD | -17505481.58% |
| ONE Bio Corp. | 6.44 Million USD | -1441.462% |
| Accustem Sciences Inc. | 3.74 Million USD | -2551.336% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -15.574% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -18572.419% |
| Q BioMed Inc. | 3.43 Million USD | -2790.338% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -301.902% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -3680.374% |
| Biomind Labs Inc. | 994.18 Thousand USD | -9891.146% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -5544.792% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -1378.564% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -5227.814% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 397420.684% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -520.417% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -5312.808% |
| GB Sciences, Inc. | 1.42 Million USD | -6892.576% |
| Alpha Cognition Inc. | 9.7 Million USD | -923.431% |
| HST Global, Inc. | 140.9 Thousand USD | -70393.425% |
| CSL Limited | 3.44 Billion USD | 97.12% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -8730.055% |
| Halberd Corporation | 74.84 Thousand USD | -132619.824% |
| Enzolytics Inc. | 2.17 Million USD | -4457.461% |
| Agentix Corp. | 1.37 Million USD | -7141.096% |
| Resverlogix Corp. | 12.71 Million USD | -681.389% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -2620.848% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 93.523% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -9414.384% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -4030.266% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -6189.287% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -2817.204% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1258.777% |
| Zenith Capital Corp. | 8.94 Million USD | -1010.703% |
| Genscript Biotech Corporation | 825.34 Million USD | 87.965% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -570074.91% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -3945.513% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -57815.428% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -5071.006% |
| Kadimastem Ltd | 2.41 Million USD | -4021.392% |
| Helix BioMedix, Inc. | 1.97 Million USD | -4936.94% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -814.053% |
| BioStem Technologies, Inc. | 22.97 Million USD | -332.344% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -54631.89% |
| LadRx Corporation | 3.81 Million USD | -2505.866% |
| Cell Source, Inc. | 4.32 Million USD | -2196.468% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -10655.722% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -10655.722% |
| NovAccess Global Inc. | 2.46 Million USD | -3926.745% |
| Affymax, Inc. | 39.38 Million USD | -152.197% |
| Itoco Inc. | 919.14 Thousand USD | -10706.825% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -2243.569% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -8776.691% |
| Mobile Lads Corp. | 554.54 Thousand USD | -17811.98% |
| CytoDyn Inc. | 18.05 Million USD | -450.062% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -394552.831% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -45034.076% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -6896.107% |
| SYBLEU INC | 160.87 Thousand USD | -61643.312% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -5368.759% |
| International Stem Cell Corporation | 5.27 Million USD | -1784.465% |
| Bioxytran, Inc. | 3.82 Million USD | -2500.166% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -188589.964% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -488176.906% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -173.893% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -6039.071% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -13398.973% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -3092.87% |
| Neutra Corp. | 243.82 Thousand USD | -40638.973% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -468.999% |
| PureTech Health plc | 144.59 Million USD | 31.306% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -384.777% |
| IXICO plc | 4.7 Million USD | -2010.265% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1029.137% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 15.642% |
| CSL Limited | 3.89 Billion USD | 97.448% |
| Cellectis S.A. | 97.32 Million USD | -2.066% |